Cargando…
Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62(P394L) mouse model of Paget's disease
Paget's disease of bone (PDB) is an age-related metabolic bone disorder, characterised by focally increased and disorganised bone remodelling initiated by abnormal and hyperactive osteoclasts. The germline P392L mutation of SQSTM1 (encoding p62) is a strong genetic risk factor for PDB in humans...
Autores principales: | Daroszewska, Anna, Rose, Lorraine, Sarsam, Nadine, Charlesworth, Gemma, Prior, Amanda, Rose, Kenneth, Ralston, Stuart H., van ‘t Hof, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177010/ https://www.ncbi.nlm.nih.gov/pubmed/30154079 http://dx.doi.org/10.1242/dmm.035576 |
Ejemplares similares
-
The Paget's disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption
por: Wani, Sachin, et al.
Publicado: (2022) -
Use of zoledronic acid in the treatment of Paget’s disease
por: Seton, Margaret, et al.
Publicado: (2007) -
Intravenous Zoledronate for a Patient with Paget's Disease
por: Kim, Ki-Choul
Publicado: (2014) -
Genetic Determinants of Paget’s Disease of Bone
por: Makaram, Navnit S., et al.
Publicado: (2021) -
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
por: Cronin, Owen, et al.
Publicado: (2019)